ASCO: Drug Combo Highly Active in Metastatic CRPC

CHICAGO (MedPage Today) -- A small cohort of men with untreated metastatic castration-resistant prostate cancer had a PSA response rate of 86% with the combination of docetaxel and abiraterone, investigators reported here.
Source: MedPage Today Geriatrics - Category: Geriatrics Source Type: news